Interferon subtypes are being investigated as treatments for COVID-191
As of June 2020, there were 51 global clinical trials using interferons, often in combination with other agents, as potential treatments for COVID-19. In any clinical trial, purity and reliability of study agents is essential.
About USP Interferon Beta-1A RS
- Qualitative and quantitative Reference Standard presented in a liquid formulation
- Each vial contains approximately 1 mg of Interferon Beta-1A
- Uses include analytical tests such as peptide mapping, HPLC-based assay and for analysis of N-linked oligosaccharides
- Typical sample chromatograms and method conditions are included in the certificate
USP Interferon Beta-1A RS
USP Catalog No: 1342401
Sign up for USP Biologics emails to be notified when this and other new USP standards are available.
USP is working throughout the COVID-19 pandemic to help ensure the supply of quality medicines and to respond to this public health crisis. We have modified USP operations to protect the health, safety and security of the staff and volunteers whose steadfast dedication inspires and enables our public health impact.